Top in hem/onc: COVID-19 effects on cancer, ASCO20 highlights
Click Here to Manage Email Alerts
Research presented at the ASCO20 Virtual Scientific Program dominated the top stories in hematology/oncology last week.
One presentation focused on the “profound” impact of the COVID-19 pandemic on cancer outcomes. Another population presentation was about the risk for poor outcomes among children with Down syndrome and acute lymphoblastic leukemia (ALL).
Source: Adobe Stock.
Read these and more top stories in hematology/oncology below:
NCI director: COVID-19 having ‘profound’ effects on cancer outcomes, research
The oncology community has demonstrated a remarkable ability to adapt amid the COVID-19 pandemic but must be prepared for its long-term effects on cancer care, National Cancer Institute Director Norman E. “Ned” Sharpless, MD, told ASCO20 Virtual Scientific Program attendees. Read more.
Children with Down syndrome, ALL at higher risk for poor outcomes
Children with Down syndrome and ALL continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program. Read more.
Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma
New data showed that adjuvant pembrolizumab (Keytruda, Merck) taken for up to 1 year conferred a durable, clinically meaningful recurrence-free survival benefit for patients with resected high-risk stage III melanoma. Read more.
CAR T-cell therapy could ‘revolutionize’ treatment of advanced multiple myeloma
JNJ-4528 (Janssen Pharmaceuticals), a chimeric antigen receptor T-cell therapy, induced early, deep and durable responses among patients with relapsed or refractory multiple myeloma, according to study results presented during the ASCO20 Virtual Scientific Program. Read more.
First-line doxorubicin plus trabectedin effective, safe for metastatic leiomyosarcoma
Doxorubicin in combination with trabectedin (Yondelis; Janssen, PharmaMar) appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program. Read more.